TEVA Q3 2025 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.5B+3.4% YoY

Gross Profit

$2.3B51.4% margin

Operating Income

$882M19.7% margin

Net Income

$433M9.7% margin

EPS (Diluted)

$0.37

QoQ Revenue Growth

+7.3%

Cash Flow

Operating Cash Flow

$369M

Free Cash Flow

$233M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$39.9B

Total Liabilities

$32.6B

Stockholders' Equity

$7.3B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.5B	$4.3B	+3.4%
Gross Profit	$2.3B	$2.1B	+7.3%
Operating Income	$882M	-$51M	+1829.4%
Net Income	$433M	-$437M	+199.1%

Revenue Segments

Product

$3.9B87%

Distribution Service

$406M9%

Product and Service, Other

$121M3%

License

$46M1%

Geographic Segments

United States Segment

$2.5B58%

Europe Segment

$1.2B29%

International Markets

$557M13%